TG Therapeutics, Inc. (TGTX) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

19/25

Growth 5 Margin 5 Expansion 3 Platform 2 Financial 4

latest quarter score

Earnings Reports

19
TG Therapeutics (TGTX) Q2 2026: U.S. Breonvi Revenue Surges 64%, Franchise Eyes $1B Run Rate
August 03, 2026
19
TG Therapeutics (TGTX) Q1 2026: BrionV Rx Base Climbs Past 25,000, Doubling Addressable Market with SubQ Path
May 06, 2026
19
TG Therapeutics (TGTX) Q4 2025: Brionvi Franchise Grows 92% as Subcutaneous Launch Nears
February 26, 2026
18
TG Therapeutics (TGTX) Q3 2025: Brionvi Net Sales Jump 93% as SubQ Pipeline Targets $10B MS Market
November 03, 2025
14
TG Therapeutics (TGTX) Q2 2025: BrionV Share Hits 33%, Sub-Q Launch Targets $8B MS Market Expansion
August 04, 2025
18
TG Therapeutics (TGTX) Q1 2025: Briomvy Revenue Jumps 137% as Repeat Prescriptions Surpass New Starts
July 07, 2025
TG Therapeutics (TGTX) Q4 2024: BRIUMVI U.S. Revenue Surges 250%, Pivotal Subcutaneous Trial Set for Mid-2025
March 03, 2025

Browse all companies